{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T21:20:46Z","timestamp":1789852846502,"version":"4.0.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Juvenile Dermatomyositis (JDM) is a rare autoimmune disorder that primarily affects muscles and skin. One of the severe complications associated with JDM is calcinosis, and treating this condition presents significant challenges. This study aimed to evaluate the efficacy and safety of local injection of infliximab into calcinosis lesions in patients with JDM.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this clinical trial, five patients diagnosed with JDM and calcinosis lesions were enrolled. The primary treatment consisted of weekly infliximab injections for 16 weeks, targeting all four sides of each lesion. Lesion dimensions, including length and width, were documented and monitored weekly. Before the intervention, patients underwent radiographic imaging. After the final injection in week 16, a follow-up radiographic assessment was performed. Data were analyzed using the Generalized Estimating Equation (GEE) method.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The lesions\u2019 size significantly decreased in both length and width during each visit. On average, the lesion length reduced by 2.66%, and the width shrank by 3.32% per visit. Based on radiographic findings, the average length and width of lesions at the initial visit were 12.09\u2009\u00b1\u20095.05\u00a0mm (range: 6.00-25.50\u00a0mm) and 6.35\u2009\u00b1\u20093.00\u00a0mm (range: 2.00\u201316.00\u00a0mm), respectively. The average length and width at the last visit were 5.59\u2009\u00b1\u20097.05\u00a0mm (range: 0\u201323.00\u00a0mm) and 3.41\u2009\u00b1\u20094.05\u00a0mm (range: 0\u201313.00\u00a0mm), respectively. No specific side effects related to the treatment were reported.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The results suggest that the direct administration of infliximab into the calcinosis lesions of patients with JDM could be a safe and effective treatment approach.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Name of the registry: The effect of infliximab injection into calcinosis lesions on patients with juvenile dermatomyositis (JDM), Trial registration number: IRCT20210808052107N1, Registration date: 2022-07-22, URL of trial registry record: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/en.irct.ir\/trial\/58329\">https:\/\/en.irct.ir\/trial\/58329<\/jats:ext-link>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12969-023-00941-5","type":"journal-article","created":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T10:02:58Z","timestamp":1704189778000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Local injection of infliximab into calcinosis lesions in patients with juvenile dermatomyositis (JDM): a clinical trial"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6906-1053","authenticated-orcid":false,"given":"Reza","family":"Shiari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8198-1012","authenticated-orcid":false,"given":"Mitra","family":"Khalili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5431-8557","authenticated-orcid":false,"given":"Vahide","family":"Zeinali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4473-2775","authenticated-orcid":false,"given":"Niloufar","family":"Shashaani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4136-958X","authenticated-orcid":false,"given":"Mohammad","family":"Samami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5055-6574","authenticated-orcid":false,"given":"Foroughossadat Hosseini","family":"Moghaddamemami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,2]]},"reference":[{"issue":"3","key":"941_CR1","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1080\/14397595.2020.1718866","volume":"30","author":"I Kobayashi","year":"2020","unstructured":"Kobayashi I, Akioka S, Kobayashi N, Iwata N, Takezaki S, Nakaseko H, et al. Clinical practice guidance for juvenile dermatomyositis (JDM) 2018-Update. Mod Rheumatol. 2020;30(3):411\u201323. https:\/\/doi.org\/10.1080\/14397595.2020.1718866.","journal-title":"Mod Rheumatol"},{"issue":"1","key":"941_CR2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/rheumatology\/keq261","volume":"50","author":"N Martin","year":"2011","unstructured":"Martin N, Krol P, Smith S, Murray K, Pilkington CA, Davidson JE, et al. A national registry for juvenile dermatomyositis and other paediatric idiopathic inflammatory myopathies: 10 years\u2019 experience; the Juvenile Dermatomyositis National (UK and Ireland) Cohort Biomarker Study and Repository for idiopathic inflammatory myopathies. Rheumatology (Oxford). 2011;50(1):137\u201345. https:\/\/doi.org\/10.1093\/rheumatology\/keq261.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"941_CR3","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s11926-019-0871-4","volume":"21","author":"D Li","year":"2019","unstructured":"Li D, Tansley SL. Juvenile dermatomyositis-clinical phenotypes. Curr Rheumatol Rep. 2019;21(12):74. https:\/\/doi.org\/10.1007\/s11926-019-0871-4.","journal-title":"Curr Rheumatol Rep"},{"key":"941_CR4","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3389\/fped.2018.00284","volume":"6","author":"C Papadopoulou","year":"2018","unstructured":"Papadopoulou C, McCann LJ. The vasculopathy of juvenile dermatomyositis. Front Pead. 2018;6:284.","journal-title":"Front Pead"},{"issue":"2","key":"941_CR5","doi-asserted-by":"publisher","first-page":"394","DOI":"10.55563\/clinexprheumatol\/56ilob","volume":"40","author":"LJ McCann","year":"2022","unstructured":"McCann LJ, Livermore P, Wilkinson MGL, Wedderburn LR. Juvenile dermatomyositis. Where are we now? Clin Exp Rheumatol. 2022;40(2):394\u2013403.","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"941_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11926-020-00974-9","volume":"23","author":"O Kul Cinar","year":"2021","unstructured":"Kul Cinar O, Papadopoulou C, Pilkington CA. Treatment of Calcinosis in Juvenile Dermatomyositis. Curr Rheumatol Rep. 2021;23(2):13. https:\/\/doi.org\/10.1007\/s11926-020-00974-9.","journal-title":"Curr Rheumatol Rep"},{"issue":"6","key":"941_CR7","doi-asserted-by":"publisher","first-page":"102533","DOI":"10.1016\/j.autrev.2020.102533","volume":"19","author":"MP Chung","year":"2020","unstructured":"Chung MP, Richardson C, Kirakossian D, Orandi AB, Saketkoo LA, Rider LG, et al. Calcinosis biomarkers in adult and juvenile Dermatomyositis. Autoimmun rev. 2020;19(6):102533. https:\/\/doi.org\/10.1016\/j.autrev.2020.102533.","journal-title":"Autoimmun rev"},{"key":"941_CR8","doi-asserted-by":"publisher","unstructured":"Huber AM. Juvenile Idiopathic Inflammatory Myopathies. Pediatric clinics of North America. 2018;65(4):739\u2009\u2013\u200956. https:\/\/doi.org\/10.1016\/j.pcl.2018.04.006.","DOI":"10.1016\/j.pcl.2018.04.006"},{"issue":"5","key":"941_CR9","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1067\/mpd.2001.112473","volume":"138","author":"M Mukamel","year":"2001","unstructured":"Mukamel M, Horev G, Mimouni M. New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment. J Pediatr. 2001;138(5):763\u20136. https:\/\/doi.org\/10.1067\/mpd.2001.112473.","journal-title":"J Pediatr"},{"issue":"12","key":"941_CR10","first-page":"2152","volume":"23","author":"MB Oliveri","year":"1996","unstructured":"Oliveri MB, Palermo R, Mautalen C, H\u00fcbscher O. Regression of calcinosis during diltiazem treatment in juvenile dermatomyositis. J Rhuematol. 1996;23(12):2152\u20135.","journal-title":"J Rhuematol"},{"issue":"10","key":"941_CR11","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1002\/1529-0131(200010)43:10<2368::AID-ANR26>3.0.CO;2-8","volume":"43","author":"LM Pachman","year":"2000","unstructured":"Pachman LM, Liotta-Davis MR, Hong DK, Kinsella TR, Mendez EP, Kinder JM, et al. TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of Tumor necrosis factor alpha, Disease duration, and pathologic calcifications. Arthritis Rheum. 2000;43(10):2368\u201377.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"941_CR12","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1006\/clim.2001.5063","volume":"100","author":"TO Fedczyna","year":"2001","unstructured":"Fedczyna TO, Lutz J, Pachman LM. Expression of TNFalpha by muscle fibers in biopsies from children with untreated juvenile dermatomyositis: association with the TNFalpha-308A allele. Clinical immunology (Orlando. Fla). 2001;100(2):236\u20139. https:\/\/doi.org\/10.1006\/clim.2001.5063.","journal-title":"Fla)"},{"key":"941_CR13","doi-asserted-by":"publisher","first-page":"369432","DOI":"10.1155\/2012\/369432","volume":"2012","author":"B De Paepe","year":"2012","unstructured":"De Paepe B, Creus KK, De Bleecker JL. The Tumor necrosis factor superfamily of cytokines in the inflammatory myopathies: potential targets for therapy. Clin Dev Immunol. 2012;2012:369432. https:\/\/doi.org\/10.1155\/2012\/369432.","journal-title":"Clin Dev Immunol"},{"issue":"9194","key":"941_CR14","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1016\/s0140-6736(99)05246-0","volume":"354","author":"R Maini","year":"1999","unstructured":"Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet (London England). 1999;354(9194):1932\u20139. https:\/\/doi.org\/10.1016\/s0140-6736(99)05246-0.","journal-title":"Lancet (London England)"},{"issue":"6 Suppl 28","key":"941_CR15","first-page":"106","volume":"20","author":"J Brandt","year":"2002","unstructured":"Brandt J, Sieper J, Braun J. Infliximab in the treatment of active and severe ankylosing spondylitis. Clin Exp Rheumatol. 2002;20(6 Suppl 28):106\u201310.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"941_CR16","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13075-020-02164-5","volume":"22","author":"R Campanilho-Marques","year":"2020","unstructured":"Campanilho-Marques R, Deakin CT, Simou S, Papadopoulou C, Wedderburn LR, Pilkington CA. Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients. Arthritis Res Therapy. 2020;22(1):79. https:\/\/doi.org\/10.1186\/s13075-020-02164-5.","journal-title":"Arthritis Res Therapy"},{"issue":"6","key":"941_CR17","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.semarthrit.2017.10.010","volume":"47","author":"A Schiffenbauer","year":"2018","unstructured":"Schiffenbauer A, Garg M, Castro C, Pokrovnichka A, Joe G, Shrader J, et al. A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis. Semin Arthritis Rheum. 2018;47(6):858\u201364. https:\/\/doi.org\/10.1016\/j.semarthrit.2017.10.010.","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"941_CR18","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1093\/rheumatology\/ken074","volume":"47","author":"P Riley","year":"2008","unstructured":"Riley P, McCann LJ, Maillard SM, Woo P, Murray KJ, Pilkington CA. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford). 2008;47(6):877\u201380. https:\/\/doi.org\/10.1093\/rheumatology\/ken074.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"941_CR19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/ibd.20318","volume":"14","author":"A Swaminath","year":"2008","unstructured":"Swaminath A, Lichtiger S. Dilation of colonic strictures by intralesional injection of infliximab in patients with Crohn\u2019s Colitis. Inflamm Bowel Dis. 2008;14(2):213\u20136. https:\/\/doi.org\/10.1002\/ibd.20318.","journal-title":"Inflamm Bowel Dis"},{"issue":"11","key":"941_CR20","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1007\/s00384-017-2899-0","volume":"32","author":"SO Adegbola","year":"2017","unstructured":"Adegbola SO, Sahnan K, Tozer PJ, Phillips RK, Faiz OD, Warusavitarne J, et al. Review of local injection of anti-TNF for perianal fistulising Crohn\u2019s Disease. Int J Colorectal Dis. 2017;32(11):1539\u201344. https:\/\/doi.org\/10.1007\/s00384-017-2899-0.","journal-title":"Int J Colorectal Dis"},{"issue":"5","key":"941_CR21","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1177\/2050640614547805","volume":"2","author":"J Hendel","year":"2014","unstructured":"Hendel J, Karstensen JG, Vilmann P. Serial intralesional injections of infliximab in small bowel Crohn\u2019s strictures are feasible and might lower inflammation. United Eur Gastroenterol J. 2014;2(5):406\u201312. https:\/\/doi.org\/10.1177\/2050640614547805.","journal-title":"United Eur Gastroenterol J"},{"issue":"4","key":"941_CR22","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1001\/archdermatol.2011.2052","volume":"148","author":"SJ Balin","year":"2012","unstructured":"Balin SJ, Wetter DA, Andersen LK, Davis MD. Calcinosis cutis occurring in association with autoimmune connective tissue Disease: the Mayo Clinic experience with 78 patients, 1996\u20132009. Arch Dermatol. 2012;148(4):455\u201362. https:\/\/doi.org\/10.1001\/archdermatol.2011.2052.","journal-title":"Arch Dermatol"},{"issue":"1","key":"941_CR23","first-page":"117","volume":"29","author":"D Guseinova","year":"2011","unstructured":"Guseinova D, Consolaro A, Trail L, Ferrari C, Pistorio A, Ruperto N, et al. Comparison of clinical features and drug therapies among European and latin American patients with juvenile dermatomyositis. Clin Exp Rheumatol. 2011;29(1):117\u201324.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"941_CR24","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3899\/jrheum.090628","volume":"37","author":"P Efthimiou","year":"2010","unstructured":"Efthimiou P, Kukar M, Kagen LJ. Images in rheumatology. Severe adult-onset calcinosis in a patient with a history of juvenile dermatomyositis. J Rhuematol. 2010;37(1):194. https:\/\/doi.org\/10.3899\/jrheum.090628.","journal-title":"J Rhuematol"},{"issue":"12","key":"941_CR25","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s11926-014-0467-y","volume":"16","author":"MF Hoeltzel","year":"2014","unstructured":"Hoeltzel MF, Oberle EJ, Robinson AB, Agarwal A, Rider LG. The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis. Curr Rheumatol Rep. 2014;16(12):467. https:\/\/doi.org\/10.1007\/s11926-014-0467-y.","journal-title":"Curr Rheumatol Rep"},{"key":"941_CR26","unstructured":"Petty RE, Laxer R, Lindsley C, Wedderburn L, Fuhlbrigge RC. ED M. Textbook of Pediatric Rheumatology E-Book. Elsevier Health Sciences; 2021."},{"issue":"7","key":"941_CR27","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1007\/s10067-006-0325-z","volume":"26","author":"S Dold","year":"2007","unstructured":"Dold S, Justiniano ME, Marquez J, Espinoza LR. Treatment of early and refractory dermatomyositis with infliximab: a report of two cases. Clin Rheumatol. 2007;26(7):1186\u20138. https:\/\/doi.org\/10.1007\/s10067-006-0325-z.","journal-title":"Clin Rheumatol"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-023-00941-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-023-00941-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-023-00941-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T10:10:50Z","timestamp":1704190250000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-023-00941-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,2]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["941"],"URL":"https:\/\/doi.org\/10.1186\/s12969-023-00941-5","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,2]]},"assertion":[{"value":"27 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Research Ethics Committee of Shahid Beheshti University of Medical Sciences (IR.SBMU.MSP.REC.1401.117). Furthermore, the study protocol was registered and confirmed in the Iranian Registry of Clinical Trails (IRCT20210808052107N1). Written informed consent was acquired from the parents of all participating patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there is no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}